Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …

Abstract Alzheimer's disease (AD), being the number one in terms of dementia burden, is an
insidious age-related neurodegenerative disease and is presently considered a global …

Background Development of in vivo biomarkers has shifted the diagnosis of Alzheimer's
disease (AD) from the later dementia stages of disease towards the earlier stages and has …

Many aspects of cognition and behaviour are regulated by noradrenergic projections to the
forebrain originating from the locus coeruleus, acting through alpha and beta …

Epidemiological studies have identified a robust association between type II diabetes
mellitus and Alzheimer disease (AD), and neurobiological studies have suggested the …

Genetic variants in the triggering receptor expressed on myeloid cells 2 (TREM2) have been
linked to Nasu-Hakola disease, Alzheimer's disease (AD), Parkinson's disease, amyotrophic …

Intense multidisciplinary research has provided detailed knowledge of the molecular
pathogenesis of Alzheimer disease (AD). This knowledge has been translated into new …

In the 12 years since the publication of the first Consensus Paper of the WFSBP on
biomarkers of neurodegenerative dementias, enormous advancement has taken place in …

Clinicopathological evidence suggests that the pathology of Alzheimer's disease (AD)
begins many years before the appearance of cognitive symptoms. Biomarkers are required …

Objective To identify biomarker patterns typical for Alzheimer disease (AD) in an
independent, unsupervised way, without using information on the clinical diagnosis. Design …